Matthew Roden, Aktis Oncology CEO (MPM Capital)
Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM's platform take
Brian Goodman, Patrick Baeuerle and Todd Foley weren’t exactly looking to start a radiopharmaceuticals company.
Rather, the team at MPM Capital — which had been known …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.